Introduction {#Sec1}
============

The two halves of the human immune system is divided as the innate and adaptive immune system, with the former being less specific as suppose to the latter. The innate immunity is the first line of defence against infections casting a wide protective net against foreign proteins. The work horse of the innate immune response is mostly present before the onset of infections and are not disease specific. The cellular and molecular components associated with the innate immune response like lysozyme, interferons, complement and toll-like receptors function by means of recognizing different classes of molecules unique to frequently encountered pathogens \[[@CR1]\]. On the other hand, the adaptive immune system is highly specific and is capable of recognizing specific foreign microorganisms and antigens to selectively eliminate them from the body. It differs from the innate immune response, as it is mainly a reaction towards a specific challenge. The adaptive immune response showcases four critical attributes that allows it to be effective in response to an infection. It shows high antigenic specificity, requires the generation of an elevated diversity of recognition entities, exhibits immunologic memory to allow a heighten response towards subsequent encounters of the same pathogen and permits recognition of self from non-self to elevate the risk of inappropriate response to self-components \[[@CR2]\]. More importantly, one should note that the innate and adaptive immune responses actually functions in sync in a cooperative manner instigating a more efficient combined response than the individual response \[[@CR1], [@CR3]--[@CR5]\].

The adaptive immune response has two major groups of cells, mainly antigen-presenting cells (APC) and lymphocytes. APC like macrophages and dendritic cells do not exhibit antigen-specific receptors but they function by processing and presenting the antigens to the antigen-specific receptors on T-cells. Lymphoytes are categorised further into two distinct cell types, namely the B-lymphocytes and T-lymphocytes \[[@CR6]\]. B-lymphocytes are essential components that protect us against invasive antigens from the environment. The B-lymphocytes upon interaction with target antigens will proliferate and produce soluble forms of the B-cell receptors commonly known as antibodies \[[@CR7]\]. The human immune system has the ability to produce a diverse collection of unique antibodies targeting a wide range of targets \[[@CR8], [@CR9]\]. These antibodies are circulating in the blood and lymphatic system to encounter foreign antigens \[[@CR10]\]. The manner by which B-cell receptors are capable of demonstrating high target specificity is hypothesised using the clonal selection theory.

At the molecular level, B-cells undergo several complex stages of development to become fully activated antibody producing cells. However, the complex diverse nature of antibody development involves genetic rearrangement and somatic hypermutation, which is crucial for the immune system to fight off any possible foreign antigens encountered \[[@CR11]\]. In this chapter, we will give a short overview of B-lymphocyte development including the repertoire generation processes. In addition to that, we will also highlight the concept and utilisation of the naïve B-lymphocyte repertoire in phage display library generation focusing on infectious diseases.

Diversification of B-Cell Repertoire {#Sec2}
------------------------------------

B lymphocytes, named after their discovery from bursa of Fabricius or bone marrow are differentiated from pluripotent hematopoietic stem cells \[[@CR12]\]. Pre-B cells are generated from progenitor cells (pro-B cells) and migrate into the fetal liver during early embryonic development \[[@CR13]\]. In the fetal liver, they develop and mature into B lymphocytes which mainly settles in epithelia, lung and gut-associated lymphoid tissues \[[@CR14]\]. B-cell development at the early bone marrow-dependent stages is concentrated along the functional rearrangement process of the heavy chain (HC) and light chain (LC) gene segments independently. This rearrangement process is capable of fabricating an extended B-cell repertoire, which is responsible for expressing a diverse pool of antibodies with an estimated diversity above 10^12^.

In general, the generation of diverse antibodies by the B-cell can be classified to two stages comprising of pre- and post-antigen stimulation. The repertoire that exist at pre-antigen stimulation is categorised as the preimmune repertoire with an estimated 10^12^ unique antibody molecules found in the human body. This initial repertoire is sufficient to isolate antibodies against a wide range of antigens \[[@CR2]\]. The diversity of the preimmune antibody repertoire is generated by the allelic diversity of the variable gene segments, V(D)J recombination, junctional diversification, pairing of both heavy and light chains, and, receptor editing \[[@CR15]\].

The variable gene (V-gene) of the HC is a result of the rearrangement of three different gene segments, being the variable (V), diversity (D) and joining (J) segments. However, the LC gene is formed by the combination of only two gene segments, the V and J gene segments. Each gene segment exist in multiple copies and the selection of different combination of the gene segments for construction of the V-gene is random. This gene rearrangement allows the formation of the initial diversity of the antibody repertoire \[[@CR16]\]. Human heavy chain V regions have at least 56 functional V gene segments, 23 D gene segments, and 6 J gene segments \[[@CR17]\].

V(D)J recombination is the primary somatic gene rearrangement of V, D, and J gene segments prior to antigen exposure \[[@CR15], [@CR18]\]. This mechanism happens in variable regions of HC and LC which encodes the antigen recognition sites. The sequence of formation allows the HC to be assembled prior to the LC \[[@CR19]\]. V(D)J recombination is initiated by the introduction of DNA double-strand breaks using recombination activating gene (RAG) proteins (RAG 1 and RAG 2) at specific recombination signal sequences (RSS). The absence of these RAG proteins can lead to the failure of lymphocyte development at progenitor stages where V(D)J recombination occurs \[[@CR20], [@CR21]\]. The recombination process is guided by a set of conserved flanking DNA sequences located next to the gene segments to ensure correct recombination. These flanking DNA sequences are known as RSS which are conserved heptamer and nanomer sequences separated by a spacer which is either 12 or 23 bp in length \[[@CR4], [@CR19]\]. The joining of two gene segments during V(D)J recombination will adapt the 12/23 rule. The V and J gene segments are flanked by a pair of 23 bp spacers while D gene segments have 12 bp spacers flanking at both ends. Therefore, this allows the joining of D gene segments to both V and J gene segments but ensures that V gene segments will not combine with J gene segments directly \[[@CR4]\]. Binding of RAG proteins to the RSS allows the formation of complexes to initiate a DNA double-strand break (DSB) in between the gene segments and RSS. The breaks are later joined by nonhomologous end-joining (NHEJ) proteins by the addition or deletion of nucleotides. This addition and deletion to the genes will further enhance the diversity of the variable regions by junctional diversification. However, not all genes produced after junctional diversification are functional, which will eventually lead to the death of these B cells \[[@CR2]\]. The gene diversification process can also lead to the formation of B cell receptors that target self-antigens. This population of B cells that targets self-antigens will undergo a further editing process termed as receptor editing. Receptor editing functions to eliminate self-reactive B cells from the system. These B cells will be stimulated to undergo further V(D)J recombination in order to edit the receptors which further enhance the diversity of antibodies \[[@CR18]\].

There is further antibody gene diversification that occurs post-antigen exposure with the ultimate aim to further diverse the repertoire. Upon exposure to antigens, antibodies perform a second wave of diversification to enhance the binding affinities against antigens via affinity maturation. Cumulative point mutations in both V regions of heavy and light chains induce affinity maturation of antibodies \[[@CR2]\]. Somatic hypermutation (SHM) and class switch recombination (CSR) are the examples which lead to affinity maturation of the antibodies upon stimulation by antigens \[[@CR22]\]. SHM diversifies the V regions and alter the affinity of antigen binding sites while CSR changes the heavy chain constant (C~H~) region to generate different antibody isotypes (IgA, IgD, IgE, IgG, and IgM) \[[@CR23], [@CR24]\]. Both SHM and CSR are initiated by somatic mutations in V regions and constant regions respectively \[[@CR25], [@CR26]\]. It was also reported that activation-induced cytidine deaminase (AID) is required by both SHM and CSR to trigger the mechanisms \[[@CR27], [@CR28]\]. AID is a 24 kDa protein that deaminates cytidine residues on single-stranded DNA (ssDNA), not RNA or double stranded DNA (dsDNA) \[[@CR23]\]. AID causes the formation of DNA lesions which is later repaired by multiple DNA repair pathways such as base excision repair (BER), mismatch repair (MMR), and NHEJ proteins \[[@CR29]\]. The role of AID in the diversification process is evident as AID deficient mice and humans are unable to carry out SHM and CSR \[[@CR30]\]. Despite happening at the same stage of B cell differentiation, SHM and CSR are different biochemical processes which are mediated by different sets of enzymes \[[@CR24]\]. SHM occurs in the germinal centers (GCs) while CSR can occur either inside or outside GCs \[[@CR31]--[@CR33]\].

SHM is a region specific mechanism which begins 150--200 base pairs (bp) downstream from the transcription start site (TSS) and is detected as far as 2 kb within the intronic region between J and C exons \[[@CR34], [@CR35]\]. AID deaminates cytosine residues in the V regions where the products of deamination lead to uracil-guanine (U-G) mismatch. This mismatch is later repaired by DNA repair mechanisms such as base excision repair and mismatch repair \[[@CR36]\]. Incorporation of point mutations by SHM in V(D)J exons of both HC an LC helps to improve antibody affinities \[[@CR37]\]. SHM occurs at a frequency of 10^−5^ to 10^−3^ mutations per base pair per generation, which is about a million times greater than the mutation rates in other genes \[[@CR38]\]. Generally, single base substitution is preferable than insertions or deletions (indel) in SHM. Also, SHM has been reported to favour certain motifs such as WRCY (W = A or T, R = A or G, C, Y = T or C), and its reverse complement RGYW motifs \[[@CR24], [@CR39]\]. Therefore, SHM is active in CDR regions where these motifs are largely presented \[[@CR40], [@CR41]\]. About two third of SHM induced substitution mutations are transition mutations as they are more preferred in SHM \[[@CR42]\]. Antibodies that have undergone SHM will produce higher affinity antigen receptors to compete with lower affinity or inactive antibodies. This selection process enables higher affinity antibodies against target specific antibodies to be concentrated \[[@CR3]\].

CSR is a mechanism that allows the antibody isotypes to be switched to initiate different mechanisms at different sites in the body. CSR switches antibody isotypes via DNA deletion and recombination on the IgH constant region upon exposure to an antigen. Therefore, CSR is vital in antibody maturation against infections and vaccines. Defective CSR has been associated with a range of diseases \[[@CR43]--[@CR45]\]. CSR occurs between switch (S) sequences that are located upstream of each constant region genes (C~H~) exon except for Cδ exons \[[@CR46], [@CR47]\]. Different immunoglobulin isotypes are encoded by different C~H~ exons which are arranged in the order of Cμ, Cδ, Cγ, Cε and Cα in heavy chains \[[@CR48]\]. Thereby, replacement of C~H~ exons with Cγ, Cε and Cα could give rises to IgG, IgA or IgE respectively. However, the V regions of antibodies will remain intact and unchanged \[[@CR32], [@CR49]\]. IgD is the only immunoglobulin isotype of the five that is generated via alternative splicing of the primary transcripts that encode IgM but not via CSR \[[@CR48]\].

The diversity generated via these molecular mechanisms is predominantly responsible for the assorted repertoire of the antibody genes. This variation provides the flexibility of the antibody repertoire to generate antibodies against a wide array of antigens with varying specificities and affinities. As the antibody repertoire is a reflection of the threats encountered by the immune system, different repertoires are formed as a result of that. Therefore variations in antibody repertoire in individuals of similar infections and different infections are expected. This will have a direct influence on the repertoire of antibodies that can be isolated from different antibody libraries used for phage display.

Antibody Phage Display Technology {#Sec3}
---------------------------------

Historically, the application of antibodies for biomedical applications was first shown with the application of antisera from hyperimmunized animals to treat botulism and diphtheria \[[@CR50]\]. The use of antisera highlighted the potential of antibodies although in a polyclonal level as a magic bullet to target infections for treatment. It was not until the introduction of hybridoma technology that production of monoclonal antibodies (mAbs) was realised. Hybridoma technology requires the fusion of immortal myeloma cells with antibody producing spleen cells to generate a hybridoma exhibiting characteristics of both myeloma and spleen cells. This characteristic allows for the infinite generation of mAbs *in vitro* \[[@CR51]\]. However, the approach requires the use of murine derived spleen cells post-immunization which have been reported to trigger human anti-mouse antibody (HAMA) response upon administration. This greatly limits the therapeutic applications of murine mAbs in humans which may result in reduced efficacy over time and in some cases anaphylaxis \[[@CR52]\]. The complications associated with the use of animal derived mAbs resulted in a string of technological advancements like CDR grafting and antibody humanization to reduce the "murine-nature" of the antibodies generated. Ultimately, the ability to generate fully human antibodies was perceived as the solution for this issue.

The introduction of phage display technology revolutionized the way antibodies was to be produced *in vitro* in the twentieth century. The application of *in vitro* display technologies like phage display has allowed the generation of fully human mAbs in greater amounts and in a more controlled manner \[[@CR53], [@CR59]--[@CR61]\]. However, phage display is no longer the only display method available for the production of human mAbs. Examples of other *in vitro* display technologies that can be used for mAb generation are ribosomal display \[[@CR54]\], yeast surface display \[[@CR55], [@CR56]\], bacterial surface display \[[@CR57], [@CR58]\] and mRNA display \[[@CR62], [@CR63]\]. The introduction of the xenograph mice technology for human antibody generation also assisted in the generation of monoclonal antibodies with the prospect of affinity maturation \[[@CR64]\]. Phage display is a promising *in vitro* display method that has been utilised successfully to isolate target specific antibodies by exploiting the Ff phages or filamentous phages \[[@CR65]\]. The important advantages of phage display that makes it a preferred alternative is the robustness, simplicity, and stability of phage particles which allows the selection of desired antibodies against different targets under predefined conditions \[[@CR66]\].

Phage display technology was first introduced by George Smith in 1985 to display peptides on the surface of phage particles as a fusion to the coat proteins \[[@CR67]\] which was ultimately exchanged with antibody fragments for the isolation of mAbs \[[@CR68]\]. Due to the non-lytic characteristic of filamentous phages (f1, fd, M13), they are commonly used in phage display to infect gram negative bacteria carrying the F pilus \[[@CR69]\]. The fundamental concept of phage display lies in the direct physical linkage between genotype and phenotype \[[@CR70]\]. The proteins or peptides encoded by the genotype are usually displayed on the phage surface by fusion with the phage coat proteins pVIII (p8) and pIII (p3) \[[@CR71], [@CR72]\] even though fusion to coat protein pVII \[[@CR73], [@CR74]\] and pIX \[[@CR74], [@CR75]\] have also been reported. The N-terminal of p3 was found to be vital for phage infectivity \[[@CR76]\]. Hence, the protein of interest fused to p3 affects the efficiency of phage infectivity and propagation \[[@CR77]\]. Phage display takes advantage of the natural process of phage infection and propagation by replicating the process with the aid of a helper phage system when using a phagemid vector. The helper phage is used in combination with the phagemid system to provide the necessary coat proteins as well as wild-type p3 for phage packaging as shown in Fig. [3.1](#Fig1){ref-type="fig"}. The phagemid vector is unique in that it is designed to contain the features from both a bacterial expression plasmid as well as a phage replication plasmid. The phagemid is normally designed to harbour the antibody gene as a fusion to gIII. Therefore the helper phage will function as the source of the remaining wild-type proteins required for phage replication, morphogenesis and assembly \[[@CR78]\].Fig. 3.1Schematic representation of phage particles bearing antibody fragments for display. The gene encoding the scFv fragment is fused to gIII in a phagemid before introduction into a bacteria carrying the F pilus. Infection of scFv fused gIII phagemid with a helper phage (M13K07) allows the helper phage to provide all necessary proteins required for phage packaging

The process for mAb generation by antibody phage display requires the presence of antibody libraries harbouring approximately 10^9^ to 10^11^ phage particles, each presenting an unique antibody clone \[[@CR79]\]. The physical isolation and enrichment of target specific mAbs from the diverse library is performed via biopanning. Biopanning is a term coined to describe the sieving process of positive clones from the diverse library and subsequent augmentation of the positive population. The biopanning process involves several repetitive cycles of binding, washing, and amplification of the positive phage clones until a predominant population is present \[[@CR70]\]. The process involves the immobilization of the target antigen on various solid surfaces such as polystyrene plates, microbeads \[[@CR80]\], nitrocellulose blots \[[@CR81]\], column matrix \[[@CR81]\] or immunoassay tips \[[@CR59]\]. The antibody phage library is then introduced to the bound target antigen and left to incubate to allow affinity based capture of the antibody bearing phage particles to the antigens. The unbound antibody-phage particles are then removed by washing. The remaining bound phage particles are then eluted using acid-based elution or enzyme based digestion. The eluted phage particles are then amplified by re-infection with *E. coli* for a fresh cycle of phage packaging. The new population of phage particles are then ready to be used for the ensuing round of biopanning. This cycle is repeated a few rounds to ensure a continuous enrichment of the targeted population of phage particles. Varying the wash and elution conditions can customize the characteristics of the isolated mAbs. This is to simulate different environments and stringencies to isolate mAbs featuring a particular characteristic.

The major limitation associated with the *E. coli* folding machinery is its ability to provide better display efficiencies of smaller versions of the antibody fragments instead of the full antibody format on phage surfaces \[[@CR82]\]. However, the presentation of full length IgG using bacterial periplasmic display was previously demonstrated to yield antibodies with nanomolar range of binding affinities \[[@CR83]\]. Even so, the use of smaller antibody fragments has a distinct advantage in terms of tissue penetration. Smaller antibody fragments are able to penetrate tissues with a higher efficacy without compromising their affinities and specificities. The diminutive size of antibody fragments that works in favour for bacterial expression host allows for an easier and faster expression of recombinant antibodies \[[@CR84], [@CR85]\]. Several common antibody formats displayed on phage includes the single-chain fragment variable (scFv) \[[@CR86], [@CR87]\] fragment antigen binding (Fab) \[[@CR88], [@CR89]\] and domain antibodies \[[@CR85]\]. The scFv format is the preferred antibody format used for phage display as it is not prone to degradation and is easier to be expressed in its functional form by bacteria \[[@CR90], [@CR91]\]. The scFv format is made up of the variable heavy chain (V~H~) and variable light chain (V~L~) domains interconnected with a glycine-serine (GS) linker \[[@CR70]\]. The application of linkers has also provided new Fab molecules in the form of single chain Fab (scFab) fragments for phage display \[[@CR88]\]. However, the choice of fragment to be used for library generation will be dependent on the downstream application of the antibodies. Possibilities to engineer new formats allow grafting of the variable domains from any format to be engineered to other subsequent formats. This freedom for format exchange allows for improved applications of antibodies for biomedical applications. Even so, the choice of format used will also have to take into account the ability to clone a large diverse collection of the clones to form a library for phage display selections. In addition to that, format conversions from scFv to full IgG have been reported to cause a loss of target affinity largely due to conformational changes in the structure post-conversion. Therefore, proper consideration and design is required before format exchange of antibody fragments is carried out \[[@CR92]\].

Construction of Naïve Antibody Library for Phage Display {#Sec4}
========================================================

As highlighted earlier, the basic requirement for antibody phage display is the accessibility of an antibody library for screening. Antibody libraries are useful assets for antibody development programs as they can be applied for various targets for multiple applications. In general, antibody libraries are classified into four categories, namely the naïve, immune, semi-synthetic and synthetic libraries. The classification of the antibody libraries are mainly influenced by the source of antibody V genes for library generation \[[@CR93]\]. Naïve antibody libraries are constructed using V genes from non-immunized donors \[[@CR93], [@CR94]\]. Immune antibody libraries however are constructed utilizing antibody V genes from immunized donors or infected individuals \[[@CR93]\]. Synthetic and semi-synthetic libraries are constructed using synthesized DNA oligonucleotides where the repertoire diversity is devoid of any natural immune maturation processes \[[@CR95]\]. This chapter will focus on the principles and characteristics of naïve libraries including the application of antibodies derived from naïve libraries in combating infectious diseases.

Naïve antibody libraries are constructed using B cells of unimmunized or healthy donors, normally focusing on the IgM isotype. Naïve libraries are supposedly able to be used for the isolation of mAbs against any antigen \[[@CR96]\]. The process involved in the generation of naïve antibody libraries is well established and has been described in numerous publications \[[@CR97]--[@CR100]\]. The human natural antibody repertoire is approximately 10^11^ in size, which is a thousand times larger than the murine naïve antibody repertoire \[[@CR101]\]. However, antibodies isolated from naïve antibody libraries usually exhibit lower affinities compared to antibodies isolated from immunized libraries. This is because the naïve repertoire would not have undergone *in vivo* affinity maturation to produce higher affinity antibodies \[[@CR96]\]. During antibody library generation, several critical aspects that are monitored includes library size and repertoire diversity in determining the quality of the library \[[@CR102]\]. In the case of naïve libraries, larger library sizes are preferred to ensure higher affinity mAbs are isolated. The correlation between larger library sizes with higher affinity mAbs has been reported in several instances as high affinity clones were successfully retrieved from larger size libraries compared to smaller size antibody libraries \[[@CR93], [@CR103], [@CR104]\].

The actual source where antibody genes are retrieved from is a vital consideration during the construction process of antibody libraries. Antibody genes could be sourced from peripheral blood mononuclear cells (PBMC), bone marrow, tonsil, and, spleen \[[@CR105]\]. However, B cells at various stages have different degrees of mutation. B cells obtained from the bone marrow are the most naïve while B cells from tonsils are the most mutated. The degree of mutation will have an adverse effect on the repertoire of the library. Therefore, the highly mutated V genes from tonsils is not an ideal choice for naïve antibody library construction but suitable for immune libraries \[[@CR106]\]. Naïve B cells are better represented by the raw V(D)J recombination in the bone marrow which have yet to encounter any antigens. The diversity of a naïve antibody library is largely dependent on the number of unique antibody sequences that is successfully cloned into the library \[[@CR61]\]. B cells are usually taken from peripheral blood for the construction of human antibody libraries as the method for extraction is less invasive compared to bone marrow extraction \[[@CR107]\]. Peripheral blood contains a high proportion of naïve B cells, making peripheral blood a very good source for B cells \[[@CR61]\]. The first naïve antibody library reported was constructed using peripheral blood lymphocytes (PBLs) of unimmunized donors with an estimated library size of greater than 10^7^. The library was successfully used to isolate soluble antibody fragments against haptens with good affinities \[[@CR108]\].

The general concern associated with naïve antibody libraries is the true nature of the sample naivety. This is due to the subjective nature of the term healthy, as it is unlikely that donors have never been infected throughout their lifetime making it realistically impossible to obtain "truly naïve" samples \[[@CR94]\]. This is because healthy individuals would have recovered from a prior infection or have been immunized at some stage in their life. Vaccinations have been reported to increase antigen-specific repertoires which could result in a skewed repertoire being generated \[[@CR109], [@CR110]\]. In addition, memory cells in the immune system are capable of recognizing past infections which could contribute to changes in the antibody repertoire \[[@CR94], [@CR111]\]. The common considerations for naïve library sample collection includes healthy donors without immunosuppressive treatments as well as antigen exposure history \[[@CR112]\], age \[[@CR113], [@CR114]\], genotype and chromatin structure \[[@CR115], [@CR116]\].

The general protocol for the construction of naïve antibody libraries using PBMC is demonstrated in Fig. [3.2](#Fig2){ref-type="fig"}. Naive antibody library construction starts with blood sample collection from a healthy population. B cells from whole blood can be isolated using the Ficoll-Hypaque density gradient centrifugation by utilizing the density differences between mononuclear cells with other elements in the blood for separation \[[@CR117]\]. Mononuclear cells such as lymphocytes, monocytes, and platelets stay on top of the Ficoll layer because they are not dense enough to penetrate the Ficoll layer. Granulocytes on the other hand sediment to the bottom of the Ficoll layer due to increased density upon contact with the Ficoll medium. Red blood cells also sediment to the bottom of Ficoll solution due to aggregation by Ficoll. Mononuclear cell layer is washed and centrifuged to remove platelets that remain in the supernatant \[[@CR117]\].Fig. 3.2General steps involved in naïve antibody library generation. Generation of naïve antibody library starts with blood sample collection from healthy donors. Total RNA is then prepared and used as template for reverse transcription into first strand cDNA by using gene specific primers. The cDNA is then amplified by polymerase chain reaction (PCR) to generate DNA amplicons. Second round of PCR is performed on these DNA samples to introduce cut sites for restriction enzymes. The amplicons are then cloned into a phagemid and transformed into suitable bacteria cells

Upon obtaining B cells, mRNA is isolated immediately and reversed transcribed into cDNA. Reverse transcription of mRNA can be carried out using either random hexamer primers or antibody specific primers. Antibody specific primers such as IgM constant region specific primers allow the cDNA synthesis of antibody sequences from the IgM isotype. However, priming using random hexamers allows all the five antibody classes (IgA, IgD, IgE, IgG, IgM) to be amplified for a highly diverse repertoire . Therefore, random hexamers are being used more often to synthesize first strand cDNA from B cell mRNA for the generation of naïve antibody libraries \[[@CR105]\]. In most cases, the preferred isotype for naïve antibody library generation is IgM. However, up to 40% of the circulating memory cells expresses IgM that may not be naïve due to somatic hypermutation upon exposure to antigens \[[@CR61]\].

Upon obtaining B cell cDNA, variable (V) regions of the heavy chain (V~H~) and light chain (V~L~) are amplified using a defined set of primers that encompasses the human antibody gene repertoires. Different primer sets have been published over the year for the amplification of all V genes \[[@CR118], [@CR119]\]. However, V gene primer designs have evolved over the years due to additional information available with improvements in sequencing technology and bioinformatics analysis. An improved database of antibody V gene sequences from next generation sequencing has shed much light into antibody gene usage and V gene family coverage. The addition of new antibody gene sequences has allowed for new primer sets to be designed with improved gene coverage \[[@CR67]\]. Improved gene coverage of the primer set has a great influence on the repertoire of the final antibody library generated. This helps to ensure all possible antibody genes are represented in the library as well as increasing the possible combinations of the HC and LC genes.

The first V gene amplification is usually done with gene specific primers without the introduction of any flanking regions. Amplification bias during PCR is a common concern that could influence the final repertoire of the library. Antibody gene usage is not evenly distributed with variations resulting from previous infections with additional variations from individual immune responses. Therefore having a highly representative primer set is important to ensure that unique gene families or poorly presented templates are also amplified \[[@CR61]\]. A second round of PCR amplification is performed to introduce the desired restriction sites for cloning into the phagemid vector. There are several different strategies to construct a naïve antibody library. The most common approaches used for the construction of naïve antibody libraries is either by two-step/three-step cloning \[[@CR94], [@CR120]\] or PCR assembly \[[@CR108]\] as shown in Fig. [3.3](#Fig3){ref-type="fig"} In two-step cloning, light chain genes are first amplified to introduce the glycine-serine linker before cloning into the phagemid vector to establish an intermediate library. Cloning of the amplified heavy chain genes to the intermediate library is done to form a full scFv format library. The orientation of which V gene to clone first is influenced by the higher diversity of the HC CDR3 regions \[[@CR121]\]. In some cases, three-step cloning is used to construct naïve antibody libraries . In this approach, independent V~H~ and V~L~ libraries are first cloned to function as intermediate libraries. Then the libraries are digested and ligated together to form the full antibody library containing both V~H~ and V~L~ repertoires \[[@CR102]\]. In PCR assembly, the V~H~ and V~L~ genes are amplified to introduce the GS linker before cloning. Then, PCR assembly is used to assemble the three fragments to form the full scFv format. The assembled fragment is then digested with restriction enzymes before cloning it upstream of the gene III coat protein in the phagemid \[[@CR97]\].Fig. 3.3Possible approaches for naïve library generation

Ligated products of antibody sequences and phagemids are transformed into bacterial cells carrying the F pilus such as XL1-Blue MRF'\[[@CR97]\], ER2738 \[[@CR122]\], TOP10F'\[[@CR123]\], *E. coli* SS 320-M13cp \[[@CR124], [@CR125]\] and TG1 \[[@CR120], [@CR126]\]. The choice of cells that are used must have high transformation efficiencies. Even so, a high number of transformation is required to overcome the limitation of *E. coli* transformation in order to generate large naïve antibody libraries \[[@CR127]\]. The library diversity is normally calculated based on the number of colonies formed from serial dilutions of transformants that are plated out on 2xYT agar and incubated overnight at 37 °C \[[@CR97], [@CR128]\]. Library developers often target for the highest library size as possible. However, this is an uphill task due to the limitations mentioned earlier. Even so, the average size for naïve antibody libraries is in the range of 10^9^ or higher. The direct correlation between library size with antibody affinity has spurred the need to generate large library sizes in order to isolate high affinity antibodies without the need to further improve the affinities \[[@CR61]\].

Isolation of Naïve Antibodies from Human Antibody Library Against Infectious Diseases {#Sec5}
=====================================================================================

There is a growing concern in terms of global health with the emergence of new infectious diseases and the re-emergence of old diseases. This situation is intensifying concerns that these diseases might eventually become pandemics \[[@CR129], [@CR130]\]. The advent of antibody based technologies has a direct impact on global health as antibodies are useful biomolecules for diagnostics and therapeutic applications. The application of antibodies in diagnostics allows for a major role in disease management and early detection systems. This is critical in the fight against infections and disease prevention. In the last decade, the identification of antibiotic resistance has highlighted the vulnerability of the human population towards new infections. This highlighted the need for new alternative treatments which includes antibody based therapies \[[@CR130]\]. Antibody based therapies appear to be a promising solution for infectious diseases due to its high specificity and the flexibility it provides in terms of modifications allows for direct programming of specific mechanisms for the treatment of specific diseases \[[@CR132]\].

Generally, immune libraries are preferred for the generation of antibodies against infectious disease related targets due to the skewed antibody repertoires as a result of exposure to the infection \[[@CR133]\]. In addition to that, high affinity antibodies could be isolated from immune libraries due to *in vivo* affinity maturation from antigen presentation \[[@CR96]\]. Therefore, the preferential repertoire against a particular disease means that libraries of smaller sized repertoires are sufficient. One major drawback for immune libraries is the inability for it to be applied across a wide range of antigens. This means that new libraries have to be constructed each time antibodies against antigens from different infections have to be generated. The major advantage of naïve libraries is the huge diversity that does not show bias towards any antigen making it a universal source of antibodies against any target antigen \[[@CR96], [@CR133]\].

Naïve Library Derived Antibodies Against Target Antigens of Infectious Agents {#Sec6}
-----------------------------------------------------------------------------

The use of antibody based therapies started as early as the 1890 when sera from immunised animals was applied to cure bacterial infections with *Clostridium tetani* and *Corynebacterium diphtheriae* \[[@CR134]\]. Since then, it has also been applied for other diseases such as tetanus, hepatitis A and B, measles, rabies, varicella, and vaccinia \[[@CR135]\]. Over the years, the developments in antibody technology allowed for antibodies to be produced at a faster rate *in vitro*. This contributed to the increase of antibody discovery projects against many different diseases. Table [3.1](#Tab1){ref-type="table"} highlights the application of naïve human antibody libraries against infectious diseases caused by virus, bacteria, fungal and parasites.Table 3.1Monoclonal antibodies against a list of infectious agentsInfectious agentTargetAntibody formatReferences**Bacterial***Bacillus subtilis* IFO 3336Native sporesscFv. FabZhou et al. \[[@CR139]\]*Lactobacillus acidophilus* ATCC 4356Intact bacteriascFvClose et al. \[[@CR143]\]*Salmonella typhi*Hemolysin E antigenscFvLim et al. \[[@CR94]\]*Bacillus anthracis*Protective antigen (PA83)scFvCirino et al. \[[@CR140]\]*Mycobacterium tuberculosis*85 BscFvFuchs et al. \[[@CR141]\]**Virus**H5N1 influenza virusHemagglutinin (HA)FabLim et al. \[[@CR145]\]Venezuelan equine encephalitis virus (VEEV)Intact virus particlesscFvKirsch et al. \[[@CR162]\]DengueNonstructural (NS) protein 5FabZhao et al. \[[@CR152]\]DengueNonstructural (NS) protein 3FabMoreland et al. \[[@CR151]\]Rabies virusscFvPansri et al. \[[@CR156]\]Hendra virusEnvelope G glycoproteinFabZhu et al. \[[@CR157]\]**Fungal***Candida albicans* 3153AHeavy and light chain variable regionsscFvHaidaris et al. \[[@CR160]\]FungalAflatoxin-BSAscFvMoghaddam et al. \[[@CR163]\]*Aspergillus fumigatus*Glycosylhydrolase Crf2scFvSchütte et al. \[[@CR164]\]**Parasite***Plasmodium falciparum*Histidine rich protein 2 (rPfHRP2)scFvLeow et al. \[[@CR165]\]

Antibody generation using traditional methods that require a living host is difficult when dealing with targets that are toxic to the host. This can be overcome by using naïve antibody libraries coupled with antibody phage display technology to allow the isolation of antibodies against antigens which are toxic or detrimental to the host \[[@CR79]\]. For instance, hemolysin E (HlyE) toxin produced by *Salmonella enterica serovar* Typhi is a pore forming toxin which is antigenic to humans, may pose a challenge for conventional antibody generation techniques \[[@CR136]\]. However, soluble scFv mAb against HlyE toxin was successfully isolated from a 2 × 10^9^ naïve human scFv library constructed from 90 healthy donors. The donors consisted of equal distribution of donors from three ethnic groups (Malay, Chinese, and Indian) and equal gender distribution. To enhance the diversity of the library, combinatorial mixing of V~H~ and V~L~ chains were performed where heavy and light chains were randomly mixed. The naïve library was generated by two-step cloning by inserting the light chains followed by heavy chains \[[@CR94]\]. The ability to harness the contrasting immune responses from different individuals resulting in varying gene rearrangements, gene pairings and usage allows for the improved diversity of the naïve library. This improved diversity ensures higher repertoire for antibody generation with improved affinities. The large library size also has a significant role in determining the antibody quality isolated from the library.

Another primary example of the application of naïve libraries is the ability to generate antibodies against the spores of *Bacillus anthracis* which can result in death post inhalation. The spores of *B. anthracis* is a potent biological threat which was abused as a bioweapon in 2001 when anthrax spores were intentionally mailed to Washington, DC \[[@CR137], [@CR138]\]. The toxic nature of the spores makes immunization for antibody generation impossible as it would most likely kill the host. Therefore, isolation of human antibodies capable of binding to live native spores is possible using a naïve scFv library. Biopanning of a naïve scFv library isolated two clones with differences in specificity and affinity to the spores of the Bacillus strains as well as recognizing different epitopes. Analysis of both clones revealed a bias in V~H~-V~L~ pairing in the repertoire after exposure of the spores to the human immune system. A naïve Fab library was later constructed by combining V~H~ and V~L~ genes from the isolated positive scFv clones with the aim to reduce the cross reactivity with other Bascillus strains. Chain shuffling technique was introduced to the Fab library to increase the diversity of V~H~ and V~L~ genes. Clones isolated from Fab library showed much lower cross reactivity with spores from other strains \[[@CR139]\]. The process was envisioned from the panning of the human naïve scFv library against the spores of *Bacillus subtilis* IFO 3336 \[[@CR139]\].

Another published work on *Bacillus anthracis* was focus at the protective antigen (PA83) which is essential for the anthrax toxicity mechanism. Several scFvs binding to PA83 were isolated from a naïve library where the highest binder exhibited *K* ~*d*~ of 50 nM. The library was generated via three-step cloning where both the V~H~ and V~L~ genes were first cloned in separate plasmid vectors to generate separate V~H~ and V~L~ libraries. The advantage of individual libraries is to supply endless material for scFv assembly \[[@CR108]\]. The size of naïve scFv library constructed was 6.7 × 10^9^ \[[@CR140]\].

A naïve human antibody library has also been used to isolate antibody fragments against tuberculosis (TB) antigens \[[@CR141]\]. TB appears to be one of the leading fatal microbial infectious diseases worldwide caused by *Mycobacterium tuberculosis* \[[@CR142]\]. A naïve library constructed using B cells from 44 donors of Caucasian, African, Indian and Chinese origin was used. Two-step cloning was applied to clone both the heavy and light chains of antibodies to create two libraries with the same heavy chain repertoire but differ in the light chain (lambda and kappa) repertoire. The libraries were validated with 110 antigens to ensure the quality of the libraries \[[@CR121]\]. The libraries were used to pan against the antigenic 85 B complex of Mtb. Five scFv clones were successfully isolated and confirmed with DNA sequencing. Four clones have lambda light chain and one with kappa light chain \[[@CR141]\].

The ability of phage display methodology to be applied to an array of different target types allows for the isolation of antibodies against various targets. A naïve antibody library was also used to pan against intact bacteria for antibody generation. The naïve scFv library isolated species-specific antibodies against *Lactobacillus acidophilus* ATCC 4356A prior to FACS quantification and genome sequencing. Generation of this naïve scFv library incorporated the use of cre-lox system which is able to generate a highly diverse library with the size of 3 × 10^11^. The phagemid with the lox site was used to infect Cre recombinase expressing bacteria, where a high number of phagemids were able to enter a single bacterium where shuffling between V~H~ and V~L~ occurred. The lox site was introduced between V~H~ and V~L~ genes to act as the scFv linker. Selection of lox site was restricted to a single basic amino acid to reduce proteolysis, removal of stop codons and is least hydrophobic in nature. Analysis showed the isolated scFv recognised the surface layer A (SlpA) protein of *L. acidophilus* which is abundant and the antibody demonstrated high degree of specificity \[[@CR143]\].

Hemagglutinin (HA) regions of influenza viruses are responsible for antigenicity of influenza viruses. Extensive mutation of these regions enabled the emergence of multiple antigenically distinct H5N1 strains \[[@CR144]\]. To overcome this issue, targeting conserved regions of protein outside the antigenic sites becomes one of the option to avoid virus escape. A combination of panning strategies was performed to isolate Fab-phage antibodies away from HA antigenic sites, towards the conserved regions of HA. Thirty three Fab antibody fragments against multiple HA were successfully isolated from naïve human Fab phage display library HX01 (Humanyx Pte Ltd., Singapore). Five out of these 33 antibodies exhibited specificity towards the conserved region HA2 which is vital for fusion of viral and cell membrane \[[@CR145]\].

Aside from isolating antibodies against the intact bacteria, naïve antibody phage library was also applied successfully to isolate antibodies against intact virus particles. Human naïve scFv library HAL4/7 was applied to pan against intact virus particles of Venezuelan equine encephalitis virus (VEEV). This is very interesting as most publications have shown isolation of naïve antibodies against virus proteins and not the intact virus particles \[[@CR146]--[@CR148]\]. The size of the naïve scFv library applied is 5 × 10^9^ and was subjected to three rounds of panning. Preselection step was performed by incubating the phage library with concentrated supernatant of non-infected Vero cells. To minimize false positive results, soluble scFvs were used in ELISA instead of scFv phage. The 11 isolated scFvs were analysed by integrative database of germ-line variable genes from immunoglobulin loci of human (VBASE2). Results demonstrated the variable domains of light chains consisting of 1, 2, 3, and 6 while 1, 3, and 4 for heavy chains.

Dengue virus of the *Flaviviridae* family has a single stranded positive strand RNA as the genome. Post translational modification of the polypeptide give rise to three structural proteins (capsid, membrane, envelope) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) \[[@CR149], [@CR150]\]. Non-structural 3 (NS3) protein and non-structural 5 (NS5) proteins are essential in viral replication which are subdivided into few distinct functional domains. Targeting these domains provides important information about dengue replication and for the development of inhibitors against dengue virus \[[@CR151], [@CR152]\]. Naïve human Fab library HX02 (Humanyx Pte Ltd., Singapore) was used to screen for NS3 binders. NS3 proteins were biotinylated to bind to streptavidin magnetic beads prior to panning. Concentration of immobilised NS3 proteins was reduced for each round with an increase in the washing steps during panning. Ten unique clones were obtained and observed to bind to the protease domain, helicase domain, or both the domains for different dengue serotypes. One clone 3F8 demonstrate the ability to bind with NS3 proteins from all dengue serotypes (DENV1-4) and has a high binding affinity (15 nM) in ELISA as well as surface plasmon resonance (SPR) with K~*D*~ 0.5 nM \[[@CR151]\]. Similar panning strategy was applied to isolate antibodies against the NS5 proteins. However, the six unique clones isolated were specific only to dengue virus serotype 3. Hence, panning was performed with alternate dengue serotypes to enrich clones which were able to recognise NS5 proteins for all serotypes. Two cross-reactive Fabs (5M1 and 5R3) and one DENV3 specific Fab (5M3) were obtained. The clones were incubated with an array of overlapping 15-mer peptides spanning the domain regions to map the epitope binding sites \[[@CR152]\]. The ability to isolate cross-reactive clones against several serotypes as well as serotype specific antigens shows the flexibility afforded when using naïve antibody libraries .

Various endeavours have been taken to select good binders from antibody phage libraries against various antigens. Approaches such as increased library sizes \[[@CR96], [@CR100]\], enhanced cloning strategies \[[@CR153]\], and improve panning protocols \[[@CR154]\] have been demonstrated to retrieve good binders. Another approach reported the use of protease sensitive helper phage KM13. This method allows high throughput screening of naive library for a wide range of antigens \[[@CR155], [@CR156]\]. The protease-cleavage sequence was inserted between domain 2 and domain 3 of pIII to eliminate background contributed by helper phage. With this KM13 helper phage, one or two rounds of selection would be needed since the number of selection did not increase the chance to obtain new binders. Naïve scFv against rabies virus was successfully isolated from a human naïve scFv library with the size of 1.5 × 10^8^ individual clones. Rabies virus is considered a difficult target due to the presence of limited amount of target in the mixture which might contribute to the enrichment of background or non-specific binders \[[@CR156]\].

*Hendra* virus (HeV) belongs to the *Henipavirus* genus of the *Paramyxovirinae* which depends on two major membrane-anchored envelope glycoproteins (G and F) for infection. This virus can cause mortality in both animal and human hosts by infecting cells with the envelope glycoproteins fused to cell membranes. Naïve Fab antibody library with an approximate size of 10^10^ was used to pan against the soluble form of glycoprotein Hendra G (sG). The library was constructed by collecting peripheral blood B cells of 10 healthy donors. Seven unique Fabs isolated from the library demonstrated longer V~H~ CDR3 among stronger binders compared to weakly bound Fabs. Isolated Fabs produced measurable inhibitory activity in reporter gene assay and inhibited syncytium formation. Later, conversion of a particular potent Fab to full antibody format exhibited 100% neutralizing potency with 12.5 μg/mL and 98% with 1.6 μg/mL \[[@CR157]\].

*Candida albicans* is a very common pathogen to humans which usually attacks immunocompromised individuals with weak immune systems \[[@CR158]\]. It has been reported that protein and carbohydrate moieties of *C. albicans* cell wall elicit strong immunological responses in humans \[[@CR159]\]. Hence, isolation of antibodies which are able to bind to these moieties could lead to a better understanding of antibody reactivity towards these surface antigens for therapeutic purposes. A combinatorial phage display scFv library was used to pan against the surface antigen of *C. albicans*. The combinatorial library consists of two scFv libraries where one derived from lambda (λ) 2 family and another one derived from kappa (κ) 3 family. Panning of antigens used roughly 10^12^ from each phage library where panning with V~L~ λ2 and V~L~ κ3 library managed to obtain enrichments of 20-fold and 300-fold respectively. Three scFv clones were isolated and confirmed to bind with blastoconidia surface antigen via immunofluorescence assay (IFA), enzyme-linked immunosorbent assay (ELISA), and western blot \[[@CR160]\].

Malaria is a life-threatening disease caused by *Plasmodium* parasites that is transmitted by mosquitoes. Out of the five species, *Plasmodium falciparum* is the most common and lethal type which leads to morbidity and mortality \[[@CR161]\]. *P. falciparum* histidine-rich protein 2 (PfHRP2) is a common candidate for the detection of *P. falciparum* infection which remains in the bloodstream up to 28 days upon infection. A naïve scFv library which was applied for isolation of antibodies against protective antigen PA83of *Bacillus anthracis* \[[@CR140]\] mentioned earlier was also used to pan against PfHRP2. This highlights the flexibility afforded by naïve libraries to be used against various disease targets simultaneously.

Potential Applications of Antibodies Derived from Naïve Antibody Libraries {#Sec7}
==========================================================================

Monoclonal antibodies are recognised as an important class of drug especially against autoimmune diseases, cancers and infectious diseases \[[@CR156], [@CR166]\]. To accommodate the increased interest in biomedical applications of antibodies, antibody phage display technology has provided an alternative for rapid discovery and broad utilisation of novel, highly specific and fully human antibodies \[[@CR167]\].

Since the introduction of monoclonal antibody technology by Kohler and Milstein in 1975, antibodies have become important biomolecules due to their capability to be applied in various fields, and most importantly in diagnostic, therapeutics, and vaccine development \[[@CR168]\]. The potential of applications of naïve antibodies isolated from naïve libraries in diagnostics had been demonstrated in few publications. Isolated scFv and Fab antibody fragments against native spores of *Bacillus subtilis* IFO 3336 were labelled with two different fluorescent dyes (FITC or rhodamine-*N*-hydroxysuccinimide) for direct and indirect detection by fluorescence microscope . The detection signal was greatly amplified when fluorescent dye was labelled to the high-copy number of phage coat protein pVIII of the antibody phage particles. Direct detection of individual spores was made possible by fluorescent-labelled antibody-phage clones \[[@CR139]\]. These spore binding antibodies could be further incorporated into other detection systems such as high-flow-rate fluidized bed as solid phase capture \[[@CR169]\], electrochemiluminescent immunoassay (ECLIA) \[[@CR170]\], and magnetic particle fluorogenic immunoassay (MPFIA) \[[@CR170]\]. Another example was demonstrated by *L. acidophilus* species specific scFv isolated with phage display technology. The resulting scFvs isolated was applied in FACS for enrichment of *L. acidophilus* which resulted in more than 99.8% genome coverage. It was envisioned that this species specific antibodies could be applied to enrich low abundance organism in a community which could lead to better taxonomic identification and genome recovery prior to genome sequencing \[[@CR143]\].

Conversion of antibody fragments into full IgG format or Fc format is always preferable for therapeutics \[[@CR171]\]. Naïve Fab antibody fragments isolated against HA region of H5N1 virus were converted into full human IgG format. These antibodies showed binding to conserved region HA2 and exhibited promising neutralization efficacy \[[@CR145]\]. Another publication reported potential therapeutic applications against Hendra virus and Nipah virus via conversion of the most potent naïve Fab into IgG1. Full-length IgG1 format has been shown to have much better cell fusion inhibitory activity with 50% lesser inhibitory concentration required \[[@CR157]\]. The naïve scFv clones against 85B antigen of TB converted into scFv-Fc (yumab) format was able to serve as a potential biomarker for the diagnostic of TB. Validation of binding between this scFv-Fc antibody and 85B antigen was performed with titration ELISA and sandwich ELISA. The lowest detection limit achieved was 5 ng/mL and 10 ng/mL respectively. Later, these antibodies were put onto the platform of lateral flow immunoassay (LFIA) for detection of 85 B by conjugating the antibodies to 40 nm colloidal gold. The assay was able to detect the antigen at ≤ 5 ng/mL. Mtb culture filtrate was also successfully detected using immunoblot, analysed by reducing gel analysis via Tape station \[[@CR141]\].

Despite the low instances of naïve antibody libraries being applied for infectious diseases, the antibodies derived from these libraries could be applied in a similar fashion for infectious disease therapy like those in oncology or autoimmunity. Antibodies can play a crucial role in neutralizing the infectivity of a virus by blocking binding sites or receptors on the virus or host cells. These class of antibodies are known as neutralizing antibodies (NAbs). Neutralization is defined as the reduction in viral infectivity via the binding of antibodies to viral surface particles which leads to the blocking of viral replication processes \[[@CR172], [@CR173]\]. Viral infection requires the attachment of the virus to the host cell membrane but different viruses may utilize different approaches for infection. Naked viruses (adenoviruses and papillomaviruses) are able to penetrate the host cell membrane to enter the cytoplasm or inject their genome through the membrane \[[@CR174]\]. While enveloped viruses (dengue viruses, zika viruses, ebola viruses) have to fuse their envelopes with hosts' membranes for attachment \[[@CR175]--[@CR177]\]. Therefore, antibodies binding to influenza virus membrane protein is able to impede the fusion of influenza viruses with host's cell membrane \[[@CR178]\].

Targeting viral envelope proteins of envelope viruses is becoming an attractive option for both diagnostic and therapy since the envelope proteins are expressed on viral surface and are therefore accessible for antibody attachment \[[@CR179]\]. For example, dengue envelope (E) protein is a common target for neutralizing antibodies and also vaccine development since it contains few neutralising epitopes and binding motifs for virus entry into host cells \[[@CR180]\]. A human Fab mAb 5J7 was shown to bind to all four dengue serotypes in enzyme-linked immunosorbent assay (ELISA) but could only neutralize dengue serotype 3. This mAb is able to neutralise 50% of dengue virus at nanogram level. Cryo-electron microscopy (cryo-EM) showed one Fab is able to bind across three E proteins and engage only domains that are crucial for infection. Moreover, the 5J7 antibody could prevent the virus from entering the host cells after attachment. The pre-attachment neutralization test showed 100% efficiency with 10 ng μL ^−1^ of antibodies \[[@CR181]\].

In some cases, polyclonal antibodies work better in detection of viral proteins such as dengue NS2B protein. NS2B protein works as a cofactor for NS3 protease activity \[[@CR182]\]. NS2B protein is small in size making it difficult to target when the whole virus particle is used. Polyclonal antibodies against NS2B proteins were generated via gene or protein immunisation in mice. Western blotting and immunofluorescence assays confirmed the polyclonal antibodies generated are able to recognise both the native and denatured form of NS2B protein \[[@CR183]\]. In certain cases such as ebola virus (EBOV) infections, an antibody cocktail is used as NAbs. Administration of antibody cocktails instead of single antibodies has shown promising results on non-human primates. Several antibody cocktails against EBOV were developed in recent years, which includes ZMAb \[[@CR184]\], MB-003 \[[@CR185]\], ZMapp \[[@CR186]\] and the combination of mAB114 with mAb100 \[[@CR187]\] that demonstrates successful therapeutic activity. ZMapp, the improved version of two antibody cocktails (MB-003 and ZMAb) reported 100% survival rate when administered to rhesus macaques despite the treatment being initiated only after 5 days of infection \[[@CR186]\]. The antibodies in the cocktail are found to target several vulnerable sites on the glycoprotein (GP). Neutralizing antibodies target the base of GP while the non-neutralizing antibodies will bind to the glycan cap and mucin-like domains which functions as an external domain for the viral attachment and fusion \[[@CR188]--[@CR192]\]. This allows for a cumulative effect on the neutralization of virus replication and prevents virus survival. The latest antibody cocktail of mAb114 and mAb100 was successful in protecting nonhuman primates against the Ebola virus disease which includes viremia. The combination of both antibodies function to target different regions of the Ebola virus to improve its efficacy. The antibody mAb100 was found to recognize the base of the Ebola virus GP trimer which prevents access to the cathepsin-cleavage loop and prevents the proteolytic cleavage of the GP that is required for virus entry. However, mAb114 was able to interact with the glycan cap and inner chalice of the GP. The antibody remains associated to the glycan cap even after proteolytic removal. This aids to inhibit the binding of the cleaved GP to its receptor. The combination effect of the two antibodies provides the basis of virus neutralization and protection against the Ebola virus \[[@CR187]\].

The cocktail approach by using several different antibodies with varying specificities and functionalities offer a broader coverage to prevent the escape of the virus \[[@CR193]\]. Aside from EBOV infections, antibody cocktails are also being applied in other viral infectious diseases such as rabies virus \[[@CR194]\], SARS coronavirus \[[@CR195]\], HIV \[[@CR196]\], hepatitis B virus \[[@CR197]\] and other viruses \[[@CR198]\]. The application of naïve antibody-cocktails is no longer something new, with the formulation and commercialization of different naïve antibody cocktails for separation of B cells and T cells from samples (Merck, BDbiosciences, Miltenyi Biotec). However, applications of naïve antibody cocktails in therapies especially infectious diseases has yet to be realised in clinical settings.

One of the major attractions in using antibodies for therapy is the ability of antibodies to induce cytotoxicity. Antibodies are able to lyse the target molecules by triggering the antibody dependent cell mediated cytotoxic (ADCC), or complement dependent cytotoxic (CDC) activity. ADCC uses immune-effector cells such as macrophages and natural killer cells while CDC function by activating a cascade of complement proteins \[[@CR199]\]. As an example, Rituximab (Rituxan^®^) targeted against the pan-B-cell marker CD20 induces cell death \[[@CR200]\]. In this regard, several other pathogens such as varicella, tetanus, Respiratory Syncytial Virus (RSV), rabies and Hepatitis B has been reported to show successful prophylactic use of antibodies in exposed individuals \[[@CR43], [@CR135]\]. In cases of immunodeficient or immunosuppressed individuals especially in HIV infected patients, antibody therapy can be a viable option for therapy because it can provide immunity to other infectious pathogens without giving rise to any further T-cell stimulation which promotes HIV growth. In addition, antibodies can be given to infections where no vaccines are available, for example, Ebola or Marburg viruses.

Antibody-drug conjugates (ADCs) are complexes of antibodies covalently joined with potent or cytotoxic drugs using various conjugation techniques. This conjugates are widely applied in cancer therapies due to their capability to differentiate healthy and disease state tissues \[[@CR201]\]. In 2015, a novel antibody-antibiotic conjugate was developed to eliminate intracellular *S. aureus*, one of the major causes of bacterial infection in the world. The anti-*S. aureus* antibodies were screened and carefully selected from peripheral blood of patients recovering from various *S. aureus* infections and linked to highly efficacious antibiotics via capthesin-cleavable linker. The conjugate eliminates *S. aureus* via two mechanisms : (1) engulf by host cells and let intracellular proteases cleave and release the antibiotic in active form; (2) binding of conjugate to bacterium and deliver antibiotic within phagosome to kill the bacterial. This conjugate was able to kill *S. aureus* inside human macrophages, endothelial and epithelial cell lines \[[@CR202]\]. Naïve antibody-drug conjugate would be a new avenue for therapy, not only in infectious diseases but also other diseases like cancer and autoimmune diseases. Conjugating drug or other potent molecules with naïve antibodies might be a promising way to overcome the limitations possess by intact naïve antibodies and conventional antibiotic treatments. Naïve libraries will likely prove to be a promising diagnostics and therapeutics tool for infectious diseases in the coming future due to their great diversity and immune-system-independent nature which gives endless possibilities to isolate antibodies targeting a wide array of disease antigens \[[@CR156]\].

Conclusion {#Sec8}
==========

Antibody based therapies have indeed been on a comeback trail after the disappointment of murine mAbs which provoke undesired immune response in humans upon administration. Despite a lot of mAbs have been approved for clinical usage, only one mAb (Palivizumab) has been approved for treatment of infectious disease. Antibody based therapies for infectious diseases are still underdeveloped and neglected due to the lack of research interest compared to cancer and other pandemic diseases. Immunised antibody libraries have always been preferred for the development of antibodies against infectious disease antigens. Skewed repertoires of immunised libraries allow isolation of high-affinity binding antibodies. However, with the rate of emerging and re-emerging infectious diseases, generation of disease specific immunised libraries is not a feasible option. Hence, a good quality naïve antibody library with a satisfactory size and diversity becomes an impeccable tool to generate antibodies against infectious diseases. Despite the antibodies isolated from naïve antibody libraries might not have satisfactory binding affinities, the advancement of molecular technology could be utilised to overcome these limitations. We believe, with the aid of newer technologies, better quality human naïve libraries could be constructed for the isolation of better quality antibodies to combat the infectious diseases. Naïve antibody phage libraries will have a foreseeable role to play in the journey to overcome the challenges posed by infectious agents.
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